Payment overview · 2025
General Payments
$512.84
16 reported records · 10 companies
Healthcare provider profile · identity verified
Michelle Wathier, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GARY, IN · NPI 1124436217
Verified facts
What the public records show
CMS Open Payments records show Michelle Wathier, NP received $512.84 in general payments during 2025 across 16 reported records.
Eisai Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $265.77 | 51.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.18 | 13.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.51 | 6.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.04 | 5.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.58 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.47 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.69 | 4.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.66 | 4.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.67 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.27 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.84 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $265.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 29 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 96 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 84 |
| Prednisone | Prednisone | 148 | 112 |
| Losartan Potassium | Losartan Potassium | 124 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 44 |
| Metformin Hcl | Metformin Hcl | 115 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 51 |
| Gabapentin | Gabapentin | 99 | 51 |
| Lisinopril | Lisinopril | 95 | 38 |
| Trazodone Hcl | Trazodone Hcl | 95 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 37 |
| Tramadol Hcl | Tramadol Hcl | 84 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 26 |
| Furosemide | Furosemide | 70 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 31 |
| Azithromycin | Azithromycin | 63 | 59 |
| Famotidine | Famotidine | 54 | 24 |
| Omeprazole | Omeprazole | 52 | 25 |
| Ozempic | Semaglutide | 52 | 21 |
| Glipizide | Glipizide | 51 | 20 |
| Montelukast Sodium | Montelukast Sodium | 51 | 22 |
| Potassium Chloride | Potassium Chloride | 50 | 28 |
| Meloxicam | Meloxicam | 49 | 24 |
| Carvedilol | Carvedilol | 48 | 23 |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 43 |
| Alprazolam | Alprazolam | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 18 |
| Allopurinol | Allopurinol | 34 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 16 |
| Farxiga | Dapagliflozin Propanediol | 30 | 12 |
| Eliquis | Apixaban | 29 | 14 |
| Linzess | Linaclotide | 29 | 12 |
| Nifedipine Er | Nifedipine | 28 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Alendronate Sodium | Alendronate Sodium | 27 | 15 |
| Simvastatin | Simvastatin | 27 | suppressed |
| Fluconazole | Fluconazole | 25 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | 12 |
| Mounjaro | Tirzepatide | 21 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.84 · 16 records | Eisai Inc. | CARDIOMEMS, CREON, Cologuard Collection Kit, GVOKE HYPOPEN, LINZESS, Leqembi, MAVYRET, MOUNJARO, Ozempic, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error